SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ray Chaudhuri K)
 

Sökning: WFRF:(Ray Chaudhuri K) > Levodopa-carbidopa ...

Levodopa-carbidopa intestinal gel in advanced Parkinson's : Final results of the GLORIA registry

Antonini, Angelo (författare)
University of Padova
Poewe, Werner (författare)
Medical University of Innsbruck
Chaudhuri, K. Ray (författare)
King's College Hospital
visa fler...
Jech, Robert (författare)
General University Hospital in Prague
Pickut, Barbara (författare)
Michigan State University
Pirtošek, Zvezdan (författare)
University Medical Centre Ljubljana
Szasz, Jozsef (författare)
George Emil Palade University of Medicine, Pharmacy, Science, and Technology
Valldeoriola, Francesc (författare)
Hospital Clínic of Barcelona
Winkler, Christian (författare)
Lindenbrunn Hospital
Bergmann, Lars (författare)
AbbVie Inc.
Yegin, Ashley (författare)
AbbVie Inc.
Onuk, Koray (författare)
AbbVie Inc.
Barch, David (författare)
AbbVie Inc.
Odin, Per (författare)
Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Restorative Parkinson Unit,Forskargrupper vid Lunds universitet,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups
visa färre...
 (creator_code:org_t)
Elsevier BV, 2017
2017
Engelska.
Ingår i: Parkinsonism and Related Disorders. - : Elsevier BV. - 1353-8020. ; 45, s. 13-20
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. Methods: Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of "On" and "Off" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. Results: Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in "Off" time (hours/day) (mean ± SD = -4.1 ± 3.5, P < 0.001), "On" time with dyskinesia (hours/day) (-1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (-16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (-7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). Conclusions: LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Levodopa-carbidopa intestinal gel
Motor symptoms
Non-motor symptoms
Parkinson's disease
Routine patient care

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy